RDHL
RedHill Biopharma Ltd.

7,225
Mkt Cap
$4.48M
Volume
6,538.00
52W High
$3.31
52W Low
$0.80
PE Ratio
-0.01
RDHL Fundamentals
Price
$0.879
Prev Close
$0.8878
Open
$0.855
50D MA
$1.07
Beta
0.89
Avg. Volume
49,110.69
EPS (Annual)
-$6.73
P/B
-0.46
Rev/Employee
$230,890.69
$3.39
Loading...
Loading...
News
all
press releases
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) DelveInsight
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight H. pylori Infections Market in the 6MM to Observe...
PR Newswire·17d ago
News Placeholder
More News
News Placeholder
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) DelveInsight
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight Biliary Tract Cancer Market is Predicted to Exhibit...
PR Newswire·19d ago
News Placeholder
Joint U.S. Commercialization of RedHill's Talicia Commences
Joint U.S. Commercialization of RedHill's Talicia Commences Joint U.S. Commercialization of RedHill's Talicia Commences PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, Feb. 25, 2026 The full sales...
PR Newswire·25d ago
News Placeholder
What's Going On With Redhill Biopharma Stock On Tuesday?
RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing GLP-1 treatment side effects and potential FDA approval paths.read more...
Benzinga·2mo ago
News Placeholder
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side...
PR Newswire·3mo ago
News Placeholder
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells PR...
PR Newswire·3mo ago
News Placeholder
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement PR...
PR Newswire·4mo ago
News Placeholder
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement PR Newswire...
PR Newswire·5mo ago
News Placeholder
RedHill Biopharma Receives Nasdaq Staff Determination Notification
RedHill Biopharma Receives Nasdaq Staff Determination Notification RedHill Biopharma Receives Nasdaq Staff Determination Notification PR Newswire TEL AVIV, Israel and RALEIGH, N.C., Oct. 22, 2025 On...
PR Newswire·5mo ago
News Placeholder
RedHill Biopharma Logs Best Session In Over A Year After $10M Legal Victory — Retail Sees Bullish Triggers Ahead
The stock rallied after the New York Supreme Court reaffirmed RedHill’s $10 million award in its dispute with Kukbo.
Stocktwits·6mo ago
<
1
2
...
>

Latest RDHL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.